250results about How to "Suitable viscosity" patented technology

The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.

A lightweight, high-strength proppant is disclosed, comprising the formation of finely dispersed ceramic precursors and sintering at low temperatures, causing the formation and retention of mesopores and micropores in pelletized ceramic. A method of manufacturing such a proppant is also disclosed, comprising the steps of manufacturing finely divided ceramic precursors and additives using grinding, milling, and preferably sol-gel processes, and dispersing the finely divided ceramic precursors and additives in a liquid, preferably water. The dispersion has a viscosity profile, which permits the shaping of spheres using conventional pelletizing techniques. Drying of the pellets and sintering at temperatures below 1,400.degrees. C. forms and retains mesopores and micropores in the ceramic. Preferred total pore volumes range from 0.05 to 0.7 cm.sup.3/g. The pelletized and porous ceramic is useful as lightweight and high-strength proppants.

Disclosed is a fermented whey preparation produced by carrying out high-temperature sterilization of an aqueous whey protein solution having a solid content of 11 to 35% by weight and a pH value adjusted to 6.5 to 8.0, then subjecting the aqueous whey protein solution to lactic acid fermentation, and homogenizing the resultant fermentation liquor as such. The fermented whey preparation has a fermentation-derived unique and good flavor and, at the same time, has a refreshed and invigorating flavor and further has a velvety texture. The fermented whey preparation is also excellent in thermal stability and safety.

The present invention is drawn to adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can have a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least two non-volatile solvents. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

The present invention is drawn to solidifying formulations for dermal delivery of a drug for treating musculoskeletal pain, inflammation, joint pain, etc. The formulation can include a drug selected from certain drug classes, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the evaporation of at least some of the volatile solvent converts the formulation on the skin into a solidified layer and the non-volatile solvent system is capable of facilitating the topical delivery of the drug(s) at therapeutically effective rates over a sustained period of time.

Novel systems and methods for performing treatment (e.g., coloration) of keratinous fibers are disclosed. The methods and systems utilize one or more of a dispensing device which is configured to provide customized composition for treating keratinous fibers (e.g., a coloring composition), optionally formed from tablets; an optical reader, for obtaining sufficient characteristics of the keratinous fibers to make a realistic prediction of the outcome of a treatment (e.g., coloring treatment); a computational units for predicting an outcome of a treatment, optionally being interfaced with the dispensing device and for selecting a customized treatment; and tablet formulations which are useful in preparing customized composition for treating keratinous fibers. Further disclosed are rapidly disintegrating tablets for use in the preparation of compositions for treating keratinous fibers.

In accordance with the present invention, there are provided novel thermosetting resin compositions which do not require solvent to provide a system having suitable viscosity for convenient handling. Invention compositions have the benefit of undergoing rapid cure. The resulting thermosets are stable to elevated temperatures, are highly flexible, have low moisture uptake and are consequently useful in a variety of applictions, e.g., in adhesive applications since they display good adhesion to both the substrate and the device attached thereto.

The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug which can treat various skin infections, such as fungal, bacterial, and/or viral skin infections. The formulation can include an anti-infective drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained period of time. The non-volatile solvent system can also act as a plasticizer for the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

A method for the thickening of mineral oil products, wherein the thickened mineral oil product exhibits shear-thinning so as to be applicable to a surface by non-pressurized spray mechanisms. The thickening agent added to the petroleum distillate comprises a thixotropic thickener chosen from the group consisting of mixtures comprising a triblock copolymer and a hydrocarbon oil, and N-Lauroyl glutamic acid di-n-butylamide.

Novel systems and methods for performing treatment (e.g., coloration) of keratinous fibers are disclosed. The methods and systems utilize one or more of a dispensing device which is configured to provide customized composition for treating keratinous fibers (e.g., a coloring composition), optionally formed from tablets; an optical reader, for obtaining sufficient characteristics of the keratinous fibers to make a realistic prediction of the outcome of a treatment (e.g., coloring treatment); a computational units for predicting an outcome of a treatment, optionally being interfaced with the dispensing device and for selecting a customized treatment; and tablet formulations which are useful in preparing customized composition for treating keratinous fibers. Further disclosed are rapidly disintegrating tablets for use in the preparation of compositions for treating keratinous fibers.

This invention provides a cleaning composition comprising a certain amount or more of an acylamino acid type surfactant, and further a non-ionic surfactant and a betaine-type ampholytic surfactant, which has a sufficient viscosity and exerts excellent conditioning effects.

A moisture-reactive hot-melt adhesive composition is provided. Particularly, a composition that includes a polyisocyanate and at least two polyols, one of which is a fatty polyol. Also provided is a method for bonding substrates using the adhesive.

The present invention relates to testosterone topical formulations, especially high testosterone concentration formulations, such as between about 6% to about 15% w/w or higher, for the controlled release of testosterone into the systemic circulation of males and females for providing constant effective testosterone blood levels, without inducing undesired testosterone spike in blood levels or testosterone transference, following topical administration. The present invention also relates to methods and pre-filled multi-dose airless applicator systems for pernasal administration of the nasal testosterone gels of the present invention

The present invention provides an adhesive comprising an acrylic polymer resin and a flame-retardant filler, in which the content of unreacted residual monomers in the adhesive, which are parts of monomers for forming the acrylic polymer resin and remain unreacted after a preparation process of the adhesive, is 2% or less by weight. Also, the present invention provides an adhesive sheet formed by applying the adhesive to one or both sides of a substrate. In addition, the present invention provides a method of controlling the flame retardancy of the adhesive by adjusting the content of the unreacted residual monomers in the adhesive.

The present invention provides a method of forming an image on a printing plate, in which a nanopaste is imagewise ink-jet applied onto a surface of a substrate. The layer is then treated to form an image area. The method is useful in the formation of printing plates and radiation opaque masks.

The invention relates to storage-stable hot-melt adhesive containing 15 to 70 wt % of a mixture of at least one copolymer based on ethylene and/or propylene and at least one C4 to C20 α-olefin which is obtainable as a block copolymer by metallocene-catalysed polymerisation, and at least one styrene block copolymer, 10 to 70 wt % of at least one tackifying resin, 0 to 40 wt % of further additives, wherein the total of the percentages should amount to 100% and the tackifying resin is entirely or in part a soft resin.

13

The present application provides for compositions comprising high concentrations of acid α-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation.